Business Wire

NY-REVIV

1.3.2024 13:36:33 CET | Business Wire | Press release

Share
Wellness Market Leaders Join Forces: The DRIPBaR Powered by REVIV

The DRIPBaR, recognized as the fastest-growing IV therapy franchise in the United States, has joined forces with REVIV, the global leader in IV therapy, marking a significant milestone for the industry. The partnership creates an unrivaled offering by bringing together the specialties of two industry heavyweights boasting over 200 locations across 6 continents, with plans to add thousands more locations in the coming years. The recent surge in demand for IV therapy presents enormous opportunities globally for the companies to redefine industry standards and spearhead the next era of IV therapy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240301173923/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Ben Crosbie, CEO of The DRIPBaR and Sarah Lomas, Founder and CEO of REVIV Global, announce their exciting partnership. (Photo: Business Wire)

With an extensive pipeline boasting over 450 franchisees in the United States, The DRIPBaR's decision to integrate REVIV's proprietary technology-backed proposition, REVIV X, validates their commitment to provide personalized and precision nutrition solutions for their customers. This partnership empowers The DRIPBaR to leverage REVIV's 10 years of intellectual property and life science expertise, utilizing objective data from blood tests and DNA analysis to tailor IV therapies to individual needs. Through REVIV X, The DRIPBaR is poised to revolutionize the wellness landscape in the United States, offering patient-focused solutions that optimize health outcomes that will solidify its position as a leader in innovation.

Ben Crosbie, CEO of The DRIPBaR, expressed excitement in the collaboration, affirming, "By selecting REVIV as our strategic partner, we are unlocking personalized and precision capabilities for a more advanced product offering and customer experience. I’m very confident that leveraging REVIV's cutting-edge technology and expertise will accelerate the growth of our franchisees and position them ahead of industry norms. The REVIV X proposition, coupled with its accredited IV Academy training course, sets a global benchmark for excellence in our field, empowering us to maintain industry leadership."

Sarah Lomas, Founder and CEO of REVIV Global, highlighted the transformative impact of the partnership, stating, "The DRIPBaR's alignment with REVIV underscores our joint dedication to innovation and safety in the IV therapy market. As industry leaders, we are reshaping the future of wellness by offering personalized and precision nutrition solutions that cater to evolving customer needs. We will continue to develop our SaaS products to power the industry globally. After many years and significant investment in research and product development, it’s exciting to see such early validation and adoption for REVIV X."

This strategic alliance between REVIV and The DRIPBaR marks a pivotal moment in the IV therapy industry and multi-modality sectors, advancing the delivery of safe, effective, and tailored wellness solutions to customers across the United States and beyond. As the IV therapy market continues its rapid expansion, with safety and compliance at the forefront, REVIV X emerges as the solution of choice for IV therapy operators, creating the opportunity for existing multi-modality businesses to access REVIV's innovative solutions and maintain their position at the forefront of wellness innovation and industry standards.

About REVIV Global

REVIV Global is at the forefront of advanced wellness solutions, devoted to enriching health and vitality through state-of-the-art IV therapy treatments. With a widespread international footprint and a relentless pursuit of innovation, REVIV is spearheading a revolution in the wellness sector. Its distinctive technological platform empowers IV therapy providers to deliver personalized and precision solutions with unparalleled safety and efficiency.

About The DRIPBaR

The DRIPBaR, a pioneering brand in the realm of wellness, is poised to redefine the landscape of health and vitality through advances in IV therapy. With cutting-edge science and a strong commitment to safety, The DRIPBaR offers a transformative approach to cellular health and personalized care. Focusing on ever-evolving treatments and medical advancements, The DRIPBaR embraces a new era of wellness where rejuvenation, vitality, and optimized health converge.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240301173923/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and

Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release

Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit

Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse

Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig

PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release

Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli

Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release

Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye